5
For years, millions of older Americans have faced an uncomfortable reality: the medications they depend on can cost significantly more in the United States than in other wealthy countries.
Now, a new federal plan intended to reduce some of those costs has triggered a legal battle between President Donald Trump’s administration and the pharmaceutical industry.
On October 7, 2026, the nation’s leading pharmaceutical trade association filed a federal lawsuit seeking to block a new Medicare drug-pricing rule.
The policy would connect payments for certain expensive medications to prices charged in 19 other countries.
The administration says the approach could reduce Medicare spending and test a new way of making American health care more affordable.
Drug manufacturers argue that federal regulators have exceeded their legal authority.
But the most surprising detail is that the rule has already been significantly weakened — and may initially affect only a handful of pharmaceutical companies.
That raises an important question for seniors: Will this legal fight actually change what Americans pay for their medications?
Reuters
+1
The Lawsuit That Could Change Medicare Drug Pricing
The legal challenge was filed by the Pharmaceutical Research and Manufacturers of America, commonly known as PhRMA.
The organization represents major companies that develop and manufacture prescription medications.
Its lawsuit was filed in the U.S. District Court for the District of Columbia against Health Secretary Robert F. Kennedy Jr. and other federal health officials.
The complaint also names the Department of Health and Human Services, the Centers for Medicare & Medicaid Services (CMS), CMS Administrator Mehmet Oz, and officials associated with Medicare’s Innovation Center.
PhRMA wants the court to invalidate the rule entirely.
The organization argues that CMS is using a program designed to test payment innovations to impose a much broader change in how Medicare determines drug prices.
In its view, a transformation of that scale requires congressional authorization.
The administration disputes that interpretation, maintaining that Congress gave CMS the authority to test precisely this kind of payment model.
Law360 Healthcare Authority
+2
The Rule at the Center of the Fight: GLOBE
The disputed policy is called the Global Benchmark for Efficient Drug Pricing, or GLOBE.
Its basic idea is relatively straightforward.
When Americans receive certain expensive medications, Medicare can pay substantially more than health systems in countries such as Canada, Germany, France, or Japan.
The administration wants to test a pricing model that uses international comparisons to calculate rebates owed by pharmaceutical manufacturers.
Under the final GLOBE rule, certain Medicare Part B drugs would be subject to benchmarks derived from prices in 19 economically comparable countries.
If a drug’s applicable U.S. price exceeds the benchmark, its manufacturer could owe additional rebates to Medicare.
Importantly, the policy does not simply order every pharmacy to lower every medication’s price.
It is a targeted Medicare payment experiment, focused on certain drugs administered in medical settings.
The administration says the model is intended to help taxpayers and beneficiaries benefit from lower international prices.
PhRMA argues that the government is effectively importing foreign price controls into Medicare.
Lawyer Monthly
+1
Which Medications Could Be Affected?
11
The GLOBE rule primarily concerns medications covered by Medicare Part B.
These are often treatments administered by doctors, nurses, or other health care professionals rather than pills picked up at a neighborhood pharmacy.
Examples of Part B drug categories include certain cancer therapies, infusions for autoimmune diseases, and injectable medications used to manage serious chronic conditions.
One medication discussed in reporting about the model is Entyvio, manufactured by Takeda and used to treat Crohn’s disease and ulcerative colitis.
However, the inclusion of a drug category in Medicare Part B does not automatically mean every medicine in that category is covered by GLOBE.
The final rule contains numerous exclusions, and the actual group of affected products is much smaller than originally proposed.
For people receiving cancer treatment or long-term infusions, the distinction matters.
A federal pricing rule may influence Medicare’s overall spending without immediately changing the amount charged at an individual doctor’s office.
Patients should not assume that a treatment’s price, coverage, or availability has already changed because of the lawsuit.
The Wall Street Journal
+1
Why Are American Drug Prices Being Compared With Other Countries?
The Trump administration’s approach is based on a long-running concern about differences between American and international prescription drug prices.
Many wealthy countries use centralized negotiations, national reimbursement systems, or other pricing mechanisms to control the cost of medications.
The United States has a more fragmented system involving government programs, private insurers, pharmacy benefit managers, manufacturers, and health care providers.
As a result, prices can vary dramatically depending on the medication and the type of coverage.
The GLOBE model is designed to test whether using international reference prices can reduce Medicare spending.
Supporters of international benchmarking argue that American taxpayers should not have to pay substantially more for comparable medications than patients and health systems overseas.
Pharmaceutical manufacturers counter that international pricing systems can restrict access to certain treatments and potentially reduce incentives to invest in new drugs.
Those concerns are central to the dispute, but the lawsuit itself primarily asks whether CMS has the legal power to implement this particular model.
PhRMA
+1
The Unexpected Detail: The Government’s Savings Estimate Has Collapsed
Perhaps the most revealing part of the controversy is how dramatically the administration changed its original proposal.
When GLOBE was first proposed, federal officials estimated that it could save Medicare approximately $11.9 billion over seven years.
But the final version contains substantial exemptions.
The government now projects savings of approximately $440 million over the same period.
How the projected Medicare savings changed
Federal estimates over seven years; figures are projections, not realized savings.
Projected savings declined by approximately 96% between the proposed and final versions.
The Washington Post
+1
That is an enormous reduction.
A program initially described as a potentially multibillion-dollar reform is now expected to produce only a fraction of the savings first anticipated.
The changes reflect exemptions for drug manufacturers that reached separate pricing agreements with the administration, as well as exclusions for certain categories of treatments.
And those exemptions lead to another surprising detail.
Why Some of America’s Biggest Drug Companies May Escape the Rule
More than two dozen drug manufacturers have reached separate pricing agreements with the Trump administration.
Among them are major companies such as Pfizer, Eli Lilly, and Novo Nordisk.
Under the final GLOBE framework, companies participating in qualifying alternative arrangements can receive exemptions.
Consequently, the number of manufacturers directly affected by GLOBE may initially be as small as four.
That has prompted questions about how much the rule will accomplish in practice.
Some health policy analysts believe companies have strong incentives to participate in other pricing arrangements if doing so allows them to avoid the more consequential Medicare Part B model.
Consumer advocates have criticized the exemptions, arguing that they reduce the potential savings for patients and taxpayers.
Drug manufacturers, meanwhile, remain concerned about the legal precedent GLOBE could establish, even if its immediate financial impact is limited.
For the pharmaceutical industry, the lawsuit is therefore about more than the cost of a few medications.
It is also about how much authority future administrations might have to establish drug prices through federal demonstration programs.
The Washington Post
+2
What the Pharmaceutical Industry Says Could Go Wrong
PhRMA has identified several objections to the policy.
The association argues that GLOBE exceeds the authority Congress granted to CMS and could discourage investment in medical research.
It also raises concerns about access to new treatments, particularly for patients with chronic illnesses, disabilities, and rare diseases.
The organization maintains that lower international prices sometimes reflect government systems that limit reimbursement or access to certain therapies.
Its position is that importing those pricing benchmarks could create similar problems in the United States.
These are the industry’s arguments, not established findings about the effects of GLOBE.
The final model has not yet produced long-term evidence showing whether it would improve affordability, restrict access, or affect pharmaceutical innovation.
That uncertainty is part of why the program was structured as a demonstration rather than an immediate nationwide overhaul.
The administration, for its part, argues that the model is consistent with the authority Congress provided to Medicare’s Innovation Center.
PhRMA
+1
Dr. Oz Defends the Government’s Approach
5
CMS Administrator Dr. Mehmet Oz has publicly defended the administration’s effort to reduce Medicare drug spending.
His agency argues that American beneficiaries and taxpayers have paid significantly more for certain medications than people in comparable countries.
The government says GLOBE is intended to test whether international price comparisons can reduce spending while maintaining care quality and encouraging medical innovation.
The administration also argues that Medicare’s Innovation Center has statutory authority to test new payment models.
PhRMA disagrees, asserting that the model goes beyond experimentation and effectively changes Medicare’s underlying payment system.
A federal judge will ultimately have to consider those competing interpretations if the litigation proceeds to a ruling on the merits.
As of the October 7 filing, the lawsuit represented a legal challenge, not a court decision declaring the rule unlawful.
The Wall Street Journal
+1
This Is Not Trump’s First Battle Over Drug Prices
The latest lawsuit has a notable historical connection.
During Trump’s first presidential term, his administration attempted to introduce another most-favored-nation pricing model for Medicare drugs.
That earlier initiative was blocked in court in 2020.
However, the court’s decision focused on procedural problems, including the administration’s failure to provide the usual opportunity for public comment before implementing the rule.
It did not establish that every form of international drug-price benchmarking is inherently unlawful.
The new GLOBE model went through a different rulemaking process.
That difference could become important as the current lawsuit moves forward.
PhRMA is again challenging the administration, but the legal arguments and regulatory record are not identical to those involved in the 2020 dispute.
AJOT
+1
What Does This Mean for Americans Over 65?
7
For seniors who depend on Medicare, the most important question is not simply whether the administration or the pharmaceutical industry wins the lawsuit.
It is whether their own prescription costs will decrease.
The answer is complicated because GLOBE affects a limited part of Medicare.
Medicare Part B generally covers medications administered in medical settings, while Medicare Part D covers many prescriptions that people fill at pharmacies.
The lawsuit concerns the GLOBE model for Part B drugs.
It does not directly challenge every Medicare prescription drug pricing program, nor does it automatically change the price of medications covered under Part D.
Even if GLOBE proceeds, a reduction in Medicare’s spending does not guarantee an equivalent reduction in every patient’s out-of-pocket bill.
That depends on the medicine, the patient’s coverage, cost-sharing rules, and how the pricing changes operate.
For seniors receiving expensive infusion treatments, the model could eventually have financial implications.
But patients should continue following their prescribed treatment plans and consult their doctors or Medicare representatives before making coverage decisions.
When Could the New Rule Take Effect?
The finalized GLOBE model is scheduled to begin on January 1, 2027.
It is designed as a five-year test rather than a permanent nationwide replacement for Medicare’s drug-pricing structure.
The model would initially operate in selected geographic areas and apply to eligible medications and manufacturers.
The legal challenge introduces uncertainty about whether the program will proceed as planned.
The court could uphold the rule, block its implementation, or require changes, depending on the arguments and evidence presented.
As of October 14, 2026, the sources reviewed establish that PhRMA has filed its complaint, but they do not establish a final court ruling on the legality of GLOBE.
That means claims that the rule has already been struck down would be premature.
The Larger Question Behind the Medicare Lawsuit
5
At its heart, the dispute reflects a larger disagreement over how the United States should address high prescription drug prices.
The Trump administration is testing whether Medicare can use international price comparisons to negotiate a better financial outcome.
The pharmaceutical industry argues that the approach exceeds federal authority and could harm medical innovation and patient access.
Consumer advocates have questioned whether the dramatically reduced program will deliver meaningful savings.
And millions of Medicare beneficiaries remain caught between those competing concerns.
The most striking aspect of the case may be the contrast between its potential legal significance and its relatively small immediate scope.
A program that could initially apply to only a few manufacturers has triggered a federal lawsuit because of what it might allow future administrations to do.
For seniors, the consequences will depend on the court’s decisions, the program’s eventual implementation, and whether savings reach patients rather than remaining solely within Medicare’s finances.
The pharmaceutical industry is fighting to stop GLOBE before it begins. The administration wants to test a new approach to lowering costs. And the question of who ultimately benefits remains unanswered.
The Medicare payment story has another twist in who may miss out on the $90 benefit. For more health headlines, read what doctors discovered after Will Friedle’s hospital scare and what’s actually known about Pope Leo XIV’s health.
